This Program encompasses a wide variety of pharmacologic, cellular, biochemical and molecular procedures basic not only to an understanding of the mechanism of action of the new anticancer agents, but also to provide important input into the design of clinical protocols. Pharmacology studies will define pharmacokinetics in mice as well as serum binding characteristics, drug distribution and metabolism in normal and tumor tissues. We have a state-of-the art instrumentation laboratory available for metabolite identification. Cellular pharmacokinetics will define the uptake, efflux and intracellular distribution of agents under study. The cellular and biochemical studies are primarily directed at determining whether the compound acts by any of the 6 standard mechanisms: alkylation, DNA binding, topoisomerase inhibition, protein synthesis inhibition, antimetabolite action or antimitotic effect. Cellular studies will define dose-response relationships in vitro as well as age-response characteristics for both cytotoxicity and progression delay. We have a sophisticated flow cytometry Core within our Cancer Center fully capable of these and other studies including cyclin level determination and quantitation of expression of mitotic proteins. A series of biochemical assays will examine drug effects on macromolecular synthesis inhibition loci. Molecular studies are directed at DNA effects examining binding as well as damage and repair kinetics; the latter assessed by alkaline elution. In addition, direct effect on topoisomerase enzymes will be assessed. Both standard and newer pulse- field electrophoresis techniques provides us with the ability to assess drug cytotoxicity mediated through an apoptotic mechanism. Newer assays directed at drug effects on membrane structures will be assessed by a variety of fluorescent probes. Presently available resistant lines as well as specifically developed lines resistant to the new agent will be used to determine mechanism of drug action and patterns of cross resistance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA053001-07S1
Application #
2779657
Study Section
Project Start
Project End
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Cruz-Rivera, Edwin; Friedlander, Michael (2011) Feeding preferences of mesograzers on aquacultured Gracilaria and sympatric algae. Aquaculture 322:218-222
Boinpally, Ramesh R; Polin, Lisa; Zhou, Sen-Lin et al. (2003) Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors. Cancer Chemother Pharmacol 52:25-33